Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. US20110071218 - Amino acid derivatives, method for preparing same, and therapeutic use thereof

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

Claims

1. A compound having the following formula (I):

          R 1NH—CH(R 2)—CH 2—S—S—CH 2—C(R 3)(R 4)—CONH—C—(R 5)(R 6)—COOR 7
wherein:
R 1 represents an (acyloxy)alkyl carbamate group

          —(CO)—O—C(R 8)(R 9)—OC(O)—R 10, wherein
R 8 and R 9 independently of each other represent a hydrogen atom, or a radical selected from the group consisting of an alkyl, aryl, arylalkyl, cycloalkyl, cycloheteroalkyl, heteroalkyl, heteroaryl and heteroarylalkyl; or
taken together, R 8 and R 9 form a 5- or 6-membered cycloalkyl;
R 10 represents a radical selected from the group consisting of an alkyl, aryl, arylalkyl, cycloalkyl, cycloheteroalkyl, heteroalkyl, heteroaryl and heteroarylalkyl;
R 2 represents:
a linear or branched, saturated hydrocarbon chain having 1 to 6 carbon atoms; or
a methylene radical substituted with a 5- or 6-membered, aromatic or saturated, heterocycle, the heteroatom being a nitrogen or sulfur atom, optionally oxidized as an N-oxide or S-oxide,
wherein the linear or branched, saturated hydrocarbon chain having 1 to 6 carbon atoms is optionally substituted with
OH, OR 11, SH, SR 11 or S(O)R 11, or
phenyl or benzyl, wherein the phenyl or benzyl is optionally substituted with 1 to 5 halogen atoms or with a radical selected from the group consisting of OH, OR 11, SH, SR 11 or S(O)R 11, R 11,
wherein R 11 is independently selected from the group consisting of a linear or branched hydrocarbon chain with 1 to 4 carbon atoms, a phenyl radical and a benzyl radical,
when R 4 represents a hydrogen atom, R 3 represents:
a phenyl or benzyl radical,
a 5- or 6-membered heteroaryl, the heteroatom being an oxygen, a sulfur or nitrogen atom; or
a methylene group substituted a 5 or 6 members, aromatic or saturated heterocycle, the heteroatom being an oxygen, nitrogen or sulfur atom, optionally oxidized as an N-oxide or S-oxide,
wherein the phenyl or benzyl radical is optionally substituted with
1 to 5 halogen atoms;
a radical selected from the group consisting of SR 11, S(O)R 11 and OR 11, R 11 having the same definition as above; or
an amino group optionally mono- or di-substituted with a cyclic or linear aliphatic group having 1 to 6 carbon atoms;
or when R 4 is different from H, R 3 and R 4 taken together form a 5- or 6-membered saturated cycle;
R 5 and R 6 independently of each other represent:
a hydrogen atom,
a linear or branched saturated hydrocarbon chain, having from 1 to 6 carbon atoms, or
a phenyl or benzyl radical,
wherein the linear or branched saturated hydrocarbon chain, having from 1 to 6 carbon atoms is optionally substituted with OH, OR 11, SH, SR 11, COOH or COOR 11, and the phenyl or benzyl radical is optionally substituted with a linear or branched alkyl chain with 1 to 4 carbon atoms, 1 to 5 halogens, or OH, OR 11, SH, or SR 11, wherein R is independently selected from the group consisting of a linear or branched hydrocarbon chain with 1 to 4 carbon atoms, a phenyl radical and a benzyl radical;
or taken together R 5 and R 6 from a saturated 5- or 6-membered cycle;
R7 represents
a hydrogen atom;
an alkyl radical having from 1 to 4 carbon atoms;
a phenyl or benzyl radical, optionally substituted by 1 to 5 halogen atoms;
a group of formula CR 12(R 13)C(O)OR 14;
a group CR 12(R 13)OC(O)R 14;
a group CR 12(R 13)OC(O)OR 14;
R 12 and R 13 independently of each other represent a hydrogen atom, or a radical selected from the group consisting of an alkyl, aryl, arylalkyl, cycloalkyl, cycloheteroalkyl, heteroalkyl, heteroaryl and heteroarylalkyl;
or taken together R 12 and R 13 may form a 5- or 6-membered cycloalkyl;
R 14 represents a radical selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, cycloheteroalkyl, heteroalkyl, heteroaryl and heteroarylalkyl; as well as the addition salts of said compound (I) with pharmaceutically acceptable mineral or organic bases and each of their enantiomers and diastereomers.
2. The compound of claim 1, wherein halogen is fluorine.
3. The compound of claim 1, wherein the radical R 1 represents an (acyloxy)alkyl carbamate group —(CO)—O—C(R 8)(R 9)—OC(O)—R 10, wherein R 8 and R 9 independently of each other represent a hydrogen atom or an alkyl group; and R 10 represents an alkyl group.
4. The compound of claim 3, wherein R 10 represents an isopropyl.
5. The compound of claim 1, wherein the radical R 2 represents an alkyl radical having from 1 to 4 carbon atoms, substituted with an SR 11 or S(O)R 11 radical, R 11 representing a radical selected from the group consisting of a linear or branched hydrocarbon chain with 1 to 4 carbon atoms, a phenyl radical and a benzyl radical.
6. The compound of claim 5, wherein R 11 represents a linear or branched saturated hydrocarbon chain with 1 to 4 carbon atoms.
7. The compound of claim 6, wherein R 11 is a methyl group.
8. The compound of claim 1, wherein the radical R 4 represents a hydrogen atom.
9. The compound of claim 8, wherein the radical R 3 represents:
a benzyl or phenyl radical, or
a methylene radical substituted with a 5- or 6-membered, aromatic or saturated, heterocycle, the heteroatom being a nitrogen of sulfur atom, optionally oxidized as an N-oxide or S-oxide.
10. The compound of claims 1, wherein the radicals R 4 and R 3 form together with the carbon atom which bears them, a 5- or 6-membered cycloalkyl.
11. The compound of claim 10, wherein the 5- or 6-membered cycloalkyl is a cyclopentane or a cyclohexane.
12. The compound of claim 1, wherein the radical R 5 represents a hydrogen atom.
13. The compound of claim 1, wherein the radical R 6 represents a hydrogen atom or an alkyl radical having from 1 to 6 carbon atoms, substituted with a radical selected from the group consisting of OH, SH, COOH and COOR 11, R 11 representing in each of these radicals a radical selected from the group consisting of a linear or branched hydrocarbon chain with 1 to 4 carbon atoms, a phenyl radical and a benzyl radical.
14. The compound of claim 1, wherein the radical R 7 represents a hydrogen atom or a radical selected from the group consisting of a phenyl, a benzyl and an alkyl radical having from 1 to 4 carbon atoms.
15. The compound of claim 1, selected from the group consisting of:
1-(1-{2-[(1-ethoxycarbonyloxy-ethoxy carbonylmethyl)-carbamoyl]-3-phenyl-propyldisulfanylmethyl}-3-methylsulfanyl-propylcarbamoyloxy)-ethyl isobutyric acid ester,
1-{1-[2-(benzyloxycarbonylmethyl-carbamoyl)-3-phenyl-propyl-disulfanylmethyl]-3-methylsulfanyl-propylcarbamoyloxy}-ethyl isobutyric acid ester,
1-{1-[2-(carboxymethyl-carbamoyl)-3-phenyl-propyl-disulfanylmethyl]-3-methylsulfanyl-propylcarbamoyloxy}-ethyl isobutyric acid ester,
1-(1-{2-[(1-ethoxycarbonyloxy-ethoxycarbonylmethyl)-carbamoyl]-3-phenyl-propyldisulfanylmethyl}-3-methane-sulfinyl-propylcarbamoloxy)-ethyl isobutyric acid ester,
1-{1-[2-benzyloxycarbonylmethyl-carbamoyl)-3-phenyl-propyl-disulfanylmethyl]-3-methanesulfinyl-propylcarbamoyloxy}-ethyl isobutyric acid ester,
1-{1-2[2-(carboxymethyl-carbamoyl)-3-phenyl-propyl-disulfanylmethyl]-3-methanesulfinyl-propylcarbamoyl-oxy}-ethyl isobutyric acid ester,
2-({1-[2-(1-isobutyryloxy-ethoxycarbonylamino)-4-methane-sulfinyl-butyldisulfanylmethyl]-cyclopentanecarbonyl}-amino)-succinic acid,
2-({1-[2-(1-isobutyryloxy-ethoxycarbonylamino)-4-methyl-sulfanyl-butyldisulfanylmethyl]-cyclopentanecarbonyl}-amino)-succinic acid,
Benzyl 2-({1-[2-(1-isobutyryloxy-ethoxycarbonylamino)-4-methanesulfinyl-butyldisulfanylmethyl]-cyclopentanecarbonyl}-amino)-succinic acid ester, and
Benzyl 2-({1-[2-(1-isobutyryloxy-ethoxycarbonylamino)-4-methylsulfanyl-butyldisulfanylmethyl]-cyclopentanecarbonyl}-amino)-succinic acid.
16. A pharmaceutical composition, comprising at least one compound having the following formula (I):

          R 1NH—CH(R 2)—CH 2—S—S—CH 2—C(R 3)(R 4)—CONH—C—(R 5)(R 6)—COOR 7
wherein:
R 1 represents an (acyloxy)alkyl carbamate group
—(CO)—O—C(R 8)(R 9)—OC(O)—R 10, wherein
R 8 and R 9 independently of each other represent a hydrogen atom, or a radical selected from the group consisting of an alkyl, aryl, arylakyl, cycloalkyl, cycloheteroalkyl, heteroalkyl, heteroaryl and heteroarylalkyl; or
taken together, R 8 and R 9 form a 5- or 6-membered cycloalkyl;
R 10 represents a radical selected from the group consisting of an alkyl, aryl, arylalkyl, cycloalkyl, cycloheteroalkyl, heteroalkyl, heteroaryl and heteroarylalkyl;
R 2 represents:
a linear or branched, saturated hydrocarbon chain having 1 to 6 carbon atoms, or
a methylene radical substituted with a 5- or 6-membered, aromatic or saturated, heterocycle, the heteroatom being a nitrogen or sulfur atom, optionally oxidized as an N-oxide or S-oxide,
wherein the linear or branched, saturated hydrocarbon chain having 1 to 6 carbon atoms is optionally substituted with
OH, OR 11, SH, SR 11, or S(O)R 11, or
phenyl or benzyl, wherein the phenyl or benzyl is optionally substituted with 1 to 5 halogen atoms or with a radical selected from the group consisting of OH, OR 11, SH, SR 11 or S(O)R 11, R 11,
wherein R 11 is independently selected from the group consisting of a linear or branched hydrocarbon chain with 1 to 4 carbon atoms, a phenyl radical and a benzyl radical,
when R 4 represents a hydrogen atom, R 3 represents:
a phenyl or benzyl radical;
a 5- or 6-membered heteroaryl, the heteroatom being an oxygen, a sulfur or nitrogen atom; or
a methylene group substituted a 5 or 6 members, aromatic or saturated heterocycle, the heteroatom being an oxygen, nitrogen or sulfur atom, optionally oxidized as an N-oxide or S-oxide;
wherein the phenyl or benzyl radical is optionally substituted with
1 to 5 halogen atoms;
a radical selected from the group consisting of SR 11, S(O)R 11 and OR 11, R 11 having the same definition as above; or
an amino group optionally mono- or di-substituted with a cyclic or linear aliphatic group having 1 to 6 carbon atoms;
or when R 4 is different from H, R 3 and R 4 taken together form a saturated 5- or 6-membered cycle;
R 5 and R 6 independently of each other represent:
a hydrogen atom,
a linear or branched saturated hydrocarbon chain, having from 1 to 6 carbon atoms, or
a phenyl or benzyl radical,
wherein the linear or branched saturated hydrocarbon chain, having from 1 to 6 carbon atoms is optionally substituted with OH, OR 11, SH, SR 11, COOH or COOR 11, and the phenyl or benzyl radical is optionally substituted with a linear or branched alkyl chain with 1 to 4 carbon atoms, with 1 to 5 halogens, or with OH, OR 11, SH or SR 11, wherein R 11 is independently selected from the group consisting of a linear or branched hydrocarbon chain with 1 to 4 carbon atoms, a phenyl radical and a benzyl radical;
or taken together R 5 and R 6 from a saturated 5- or 6-membered cycle;
R7 represents
a hydrogen atom;
an alkyl radical haying from 1 to 4 carbon atoms;
a phenyl or benzyl radical, optionally substituted by 1 to 5 halogen atoms;
a group of formula CR 12(R 13)C(O)OR 14;
a group CR 12(R 13)OC(O)R 14; or
a group CR 12(R 13)OC(O)OR 14,
R 12 and R 13 independently of each other represent a hydrogen atom, or a radical selected from the group consisting of an alkyl, aryl, arylalkyl, cycloalkyl, cycloheteroalkyl, heteroalkyl, heteroaryl and heteroarylalkyl;
or taken together R 12 and R 13 may form a 5- or 6-membered cycloalkyl;
R 14 represents a radical selected from the group consisting of alkyl, aryl, arylalkyl, cycloalkyl, cycloheteroalkyl, heteroalkyl, heteroaryl and heteroarylalkyl; as well as the addition salts of said compound (I) with pharmaceutically acceptable mineral or organic bases and each of their enantiomers or diastereomers, and a pharmaceutically appropriate excipient.
17. The composition of claim 16, wherein the excipient is appropriate for administration via an oral, nasal or intravenous route.
18. The pharmaceutical composition of claim 16, further comprising at least one compound selected from the group consisting of cannabinoids, morphine, and derivatives of Gaba selected from the group consisting of gabapentin and pregabalin.
19. The composition of claim 18, wherein the cannabinoid is Δ 9-tetrahydrocannabinol.